Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
|Slideshows|October 12, 2017
How to Use Light Therapy in Bipolar Disorder
Author(s)Chris Aiken, MD
A novel protocol lights the way for a promising treatment for bipolar depression.
Advertisement
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
2
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
3
Brenipatide for Alcohol Use Disorder: Emerging Findings
4
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
5